6533b85cfe1ef96bd12bcbcd
RESEARCH PRODUCT
Web searches for anxiolytic drugs during the COVID-19 outbreak in the USA
Brandon Michael HenryFabian Sanchis-gomarGiuseppe Lippisubject
2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Population030226 pharmacology & pharmacyDisease Outbreaks03 medical and health sciencessocial medicine0302 clinical medicinePandemicHumansMedicine030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticseducationeducation.field_of_studyBrand namesSARS-CoV-2business.industryPublic healthpublic healthOutbreakCOVID-19Anxiolytic drugsUnited Statesprimary health careAnti-Anxiety AgentsCOVID-19 mental health primary health care public health social medicinebusinessmental healthDemographydescription
Several lines of evidence attest that the ongoing coronavirus disease 2019 (COVID-19) pandemic is accompanied by a vast array of physiological problems in the community.1 Since the emergence or magnification of anxiety disorders in the general population has also been suggested during the COVID-19 outbreak,2 we aimed to provide further insights on this matter by performing an electronic search in Google Trends (Google Inc, Mountain View, CA, USA), using the terms corresponding to the most common anxiolytic medicines used in the USA (ie, ‘Alprazolam’, ‘Diazepam’, ‘Lorazepam’, and ‘Clonazepam’) along with their brand names (‘Xanax’, ‘Valium’, ‘Ativan’, and ‘Klonopin’, respectively), and setting the country option to ‘United States’. The weekly Google Trends score recorded for each of the keywords after the emergence of the COVID-19 outbreak in the USA (ie, between 19 January to 18 November 2020) was compared with the average score recorded during each corresponding week of the previous 4 years (ie, between 19 January 2016 to 8 November 2019). The overall number of new weekly …
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-01-27 |